{"id": 225021488, "title": "NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials", "text": "As of March 31, 2024, the Company had cash and cash equivalents of US$3.25 million (December 31, 2023 \u2013 US$0.54 million) and working capital of US$3.31 million (December 31, 2023 \u2013 US$0.07 million). The increase in cash was primarily due to the completion of a private placement in January 2024 for gross proceeds of approximately US$1.49 million and the exercise of warrants in March 2024 for gross proceeds of approximately US$2.92 million. The Company had an accumulated deficit of US$14.98 million as of March 31, 2024, (December 31, 2023 \u2013 US$14.06 million). Eran Ovadya, NurExone\u2019s Chief Financial Officer, added: \u201cThe Company maintains a strong cash position, ensuring sufficient funding until year-end. With strategic oversight, we navigate our business plan amidst ongoing activities, positioning ourselves for sustained growth and continued success.\u201d About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company\u2019s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.", "summary": "TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the \u201cCompany\u201d or \u201cNurExone\u201d), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in [&#8230;]", "url": "https://financialpost.com/globe-newswire/nurexone-reports-first-quarter-2024-financial-results-and-provides-corporate-update-moving-forward-with-fda-guidelines-for-the-human-trials", "image": "https://smartcdn.gprod.postmedia.digital/financialpost/wp-content/uploads/2024/05/commuters-on-bay-street-as-canadian-stocks-mixed.jpg?quality=5&strip=all&w=100&sig=gCsOruxPhrA8bPqdSVYb6g", "video": null, "publish_date": "2024-05-29 12:39:39", "author": "GlobeNewswire", "authors": ["GlobeNewswire"], "language": "en", "source_country": "CA", "sentiment": -0.058}